ctcae grading - Health Topics
ascopubs.org: Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents. Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents. To examine concordance in symptomatic adverse event (AE) grading using the Common Terminology Criteria for Adverse Events (CTCAE 4.0) for clinicians and its patient-reported outcome (PRO) versions for ...
Understanding the Context
This tutorial provides practical guidance on applying CTCAE to AE grading in compliance with clinical research standards. What is the CTCAE Grading System? Created by the National Cancer Institute (NCI), the CTCAE scale was designed to create a globally recognized system for grading and defining adverse events experienced by the patients in cancer drug clinical trials. CTCAE Grading System and Management CTCAE (Common Terminology Criteria for Adverse Events) uses a 5-grade severity scale (Grade 1-5) where Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death, with management escalating from continuing treatment with supportive care at Grade 1 to immediate ...
Image Gallery
Key Insights
The NCI Common Terminology Criteria for Adverse Events is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. This topic presents selected tables describing some of the AEs graded using the NCI CTCAE version 6.0, which was published in 2025 [1]; it also provides references for other adverse event reporting systems.